Business
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.","length":480,"tagName":"p"},{"type":"image","alt":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)","displaySize":"","headline":null,"caption":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation) (PRNewsfoto/CytoSorbents Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":185,"url":"https://media.zenfs.com/en/prnewswire.com/60064ee123b2486ff06bf22679aad801"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vyx_W5YQZ5KQRkzzHXw_Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/60064ee123b2486ff06bf22679aad801","width":400,"height":185}},"href":"https://mma.prnewswire.com/media/2754298/CytoSorbents_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Investors attending the conference can schedule a meeting with management through the conference website. For more information, please contact the Company's investor relations tea...